SEC Form 4 · accession 0000920465-18-000062
LA JOLLA PHARMACEUTICAL CO · LJPC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George F Tidmarsh
Officer — President, CEO & Secretary · Director
Period of report
Nov 30, 2018
Accepted (ET)
Dec 3, 2018 · 9:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920465
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 30, 2018 | A | 100 | $12.2995 | A | 1,281,060 | D | |
| Common Stock | holding | — | — | — | 22,000 | I | By children |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $14.47 | Nov 30, 2018 | A | 100 | A | — | Nov 30, 2028 | Common Stock | 100 | 100 | D |
Explanation of responses
- F1These shares were acquired on 11/30/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.